Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Common Equity: 2014-2024

Historic Common Equity for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to $517.8 million.

  • Spyre Therapeutics' Common Equity rose 39.01% to $455.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.1 million, marking a year-over-year increase of 39.01%. This contributed to the annual value of $517.8 million for FY2024, which is 181.39% up from last year.
  • As of FY2024, Spyre Therapeutics' Common Equity stood at $517.8 million, which was up 181.39% from $184.0 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Common Equity registered a high of $517.8 million during FY2024, and its lowest value of $50.3 million during FY2022.
  • In the last 3 years, Spyre Therapeutics' Common Equity had a median value of $184.0 million in 2023 and averaged $250.7 million.
  • In the last 5 years, Spyre Therapeutics' Common Equity plummeted by 40.07% in 2022 and then spiked by 265.80% in 2023.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Common Equity stood at $139.8 million in 2020, then plummeted by 39.97% to $83.9 million in 2021, then plummeted by 40.07% to $50.3 million in 2022, then skyrocketed by 265.80% to $184.0 million in 2023, then spiked by 181.39% to $517.8 million in 2024.